Management of Calciphylaxis
Adopt a multimodal approach prioritizing aggressive wound care, intensive pain management, limiting calcium/phosphate exposure, and avoiding vitamin K antagonists, while recognizing that sodium thiosulfate—despite widespread use—lacks proven efficacy for wound healing or survival. 1
Core Management Principles
The 2025 KDIGO guidelines emphasize that calciphylaxis management requires addressing multiple domains simultaneously: advanced care planning, pain control, shared decision-making, and dialysis optimization 1. Importantly, serum calcium and phosphate levels cannot guide therapy or predict outcomes, but limiting excess exposure to both remains critical 1.
Risk Factor Modification
- Immediately discontinue vitamin K antagonists (warfarin) - associated with up to 11-fold increased risk of calciphylaxis 1
- For patients requiring anticoagulation with atrial fibrillation on dialysis: consider reduced-dose apixaban as a safer alternative 1
- Avoid high-dose active vitamin D derivatives (calcification inducers) 1
- Minimize calcium-containing phosphate binders
Pain Management
Pain control is paramount given the devastating impact on quality of life 2, 3, 4. A multimodal analgesic strategy is essential 5:
- Renal-sparing opioids as primary agents
- Nerve blocks for regional control
- Ketamine for severe, refractory pain
- Benzodiazepines as adjuncts
- Avoid NSAIDs in patients with significant renal impairment
Surgical excision, when indicated for intractable pain or infection, has demonstrated effectiveness in reducing narcotic requirements (83.3% of survivors off narcotics post-healing) 6.
Wound Care
Aggressive, meticulous wound care is the cornerstone of management 2, 3, 6:
- Gentle debridement of necrotic tissue (avoid traumatizing viable tissue)
- Infection surveillance and prompt antimicrobial therapy
- Advanced wound dressings appropriate for wound characteristics
- Consider cadaveric skin substitutes in select cases 2
- Lymphedema therapy when applicable 2
Critical caveat: Skin biopsy has 20-80% sensitivity, 30% inadequate sampling rate, and risks triggering additional non-healing ulcers 1. Diagnosis should rely primarily on clinical suspicion based on patient history, presentation, and risk factors 2. Only pursue biopsy when diagnosis significantly alters management and benefits outweigh risks.
Pharmacologic Interventions
Sodium Thiosulfate - The Evidence Gap
Despite widespread use, sodium thiosulfate has never been evaluated in a randomized controlled trial for calciphylaxis, and recent meta-analysis found no association with wound improvement or survival 1. Dosing when used: 12.5-25 g per dialysis session, 2-3 times weekly 1. Be aware of dose-dependent adverse effects including hip bone mineral density decline 1.
Emerging Therapies
SNF472 showed promise in the CALCIPHYX trial with similar wound healing improvements versus placebo (measured by modified Bates Jensen Wound Assessment Tool and Pain Visual Analogue Scale), plus fewer deaths and hospitalizations 1. However, this remains investigational.
Surgical Management
Surgery is indicated for 6:
- Intractable pain (100% of surgical cases)
- Infection/sepsis (54.5% of surgical cases)
Surgical approach involves serial excisional debridements (average 2.9 procedures), with closure options including:
- Healing by secondary intention (29.4%)
- Primary closure (23.5%)
- Local flaps (27.3%)
Mean time to healing: 57 days post-final excision 6. Complications include dehiscence (9%), cellulitis progression (18%), osteomyelitis (9%), and amputation (18%) 6.
Important reality check: Despite intervention, 1-year mortality approaches 50%, with average survival of 4.8 months in fatal cases 6, 4. However, among survivors, 75% achieve ambulatory status 6.
Dialysis Considerations
Optimize dialysis prescription and consider dialysate composition adjustments, though specific parameters require individualization based on patient's mineral metabolism 1.